CDH17 and rheumatoid arthritis: Therefore, they confirm that a structure-based approach to the identification of effective cell–cell junction modulators to be used as antiangiogenic drugs for the treatment of cadherin-expressing solid tumors, as anti-inflammatory drugs against RA or as potential pharmaceutical excipients to facilitate drug delivery across biological barriers is now possible.